Brokerages expect Check Cap Ltd (NASDAQ:CHEK) to announce earnings per share (EPS) of ($0.82) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Check Cap’s earnings. Check Cap posted earnings per share of ($1.92) in the same quarter last year, which would suggest a positive year-over-year growth rate of 57.3%. The company is scheduled to announce its next quarterly earnings report on Thursday, August 9th.
According to Zacks, analysts expect that Check Cap will report full-year earnings of ($4.99) per share for the current financial year, with EPS estimates ranging from ($7.20) to ($2.77). For the next year, analysts forecast that the firm will post earnings of ($1.36) per share. Zacks’ earnings per share averages are an average based on a survey of research analysts that follow Check Cap.
Check Cap (NASDAQ:CHEK) last announced its quarterly earnings results on Thursday, May 17th. The medical research company reported ($1.27) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.68) by $0.41.
Several equities analysts have issued reports on the stock. HC Wainwright restated a “buy” rating and issued a $14.00 price target on shares of Check Cap in a research report on Wednesday, May 23rd. Zacks Investment Research upgraded shares of Check Cap from a “hold” rating to a “buy” rating and set a $5.00 price target for the company in a research report on Wednesday, May 9th. Finally, ValuEngine upgraded shares of Check Cap from a “sell” rating to a “hold” rating in a research report on Wednesday, April 4th.
An institutional investor recently bought a new position in Check Cap stock. Armistice Capital LLC acquired a new stake in Check Cap Ltd (NASDAQ:CHEK) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 748,000 shares of the medical research company’s stock, valued at approximately $651,000. Armistice Capital LLC owned about 3.88% of Check Cap as of its most recent filing with the SEC.
NASDAQ CHEK traded up $0.12 on Monday, hitting $4.23. The company’s stock had a trading volume of 249,684 shares. Check Cap has a 1-year low of $3.12 and a 1-year high of $24.00.
Check Cap Company Profile
Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based system that utilizes low-dose X-rays for screening of the colon to detect polyps, masses, and colorectal cancers in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule, which is designed to measure, collect, and transmit structural information; C-Scan Track, a biocompatible unit worn on the patient's back for capsule control, tracking, and data recording; and C-Scan View, a personal computer-based software package, which is designed to retrieve and process clinical data from the C-Scan Track, and to reconstruct and produce 3D visualization of the colon's inner surface.
Get a free copy of the Zacks research report on Check Cap (CHEK)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Check Cap Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Check Cap and related companies with MarketBeat.com's FREE daily email newsletter.